Disease-free survival · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy
Oral showed no clear difference in disease‐free survival compared with intravenous fluoropyrimidines (moderate certainty).
1 finding from 1 review
Grade ≥ 3 neutropenia/granulocytopenia · Patients treated with palliative intent for inoperable advanced or metastatic colorectal cancer with chemotherapy
Oral may leads to lower grade ≥ 3 neutropenia/granulocytopenia compared with intravenous fluoropyrimidines (low certainty).
1 finding from 1 review
Overall survival · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy
Oral showed no clear difference in overall survival compared with intravenous fluoropyrimidines (high certainty).
1 finding from 1 review
Grade ≥ 3 diarrhoea · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy
It is very uncertain whether oral changes grade ≥ 3 diarrhoea compared with intravenous fluoropyrimidines (very low certainty).
1 finding from 1 review
Hand‐foot syndrome (grade ≥ 3) · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy
Oral may leads to higher grade ≥ 3 hand foot syndrome compared with intravenous fluoropyrimidines (low certainty).
1 finding from 1 review
Grade ≥ 3 neutropenia/granulocytopenia · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy
Oral probably leads to lower grade ≥ 3 neutropenia/granulocytopenia compared with intravenous fluoropyrimidines (moderate certainty).
1 finding from 1 review
Progression‐free survival · Patients treated with palliative intent for inoperable advanced or metastatic colorectal cancer with chemotherapy
Oral probably leads to higher progression‐free survival compared with intravenous fluoropyrimidines (moderate certainty).
1 finding from 1 review
Overall survival · Patients treated with palliative intent for inoperable advanced or metastatic colorectal cancer with chemotherapy
Oral showed no clear difference in overall survival compared with intravenous fluoropyrimidines (high certainty).
1 finding from 1 review
Grade ≥ 3 diarrhoea · Patients treated with palliative intent for inoperable advanced or metastatic colorectal cancer with chemotherapy
Oral may leads to higher grade ≥ 3 diarrhoea compared with intravenous fluoropyrimidines (low certainty).
1 finding from 1 review
Hand‐foot syndrome (grade ≥ 3) · Patients treated with palliative intent for inoperable advanced or metastatic colorectal cancer with chemotherapy
Oral probably leads to higher grade ≥ 3 hand foot syndrome compared with intravenous fluoropyrimidines (moderate certainty).
1 finding from 1 review
Non‐infectious complications · people undergoing gastrointestinal surgery
Oral nutritional supplements showed no clear difference in non‐infectious complications recorded up to 30 days postdischarge compared with usual care or control (low certainty).
1 finding from 1 review
Infectious complications · people undergoing gastrointestinal surgery
It is very uncertain whether oral nutritional supplements changes infectious complications recorded up to 30 days postdischarge compared with usual care or control (very low certainty).
1 finding from 1 review
Length of hospital stay · people undergoing gastrointestinal surgery
1 finding from 1 review
Adverse effects · people undergoing gastrointestinal surgery
1 finding from 1 review
Infectious complications · people undergoing gastrointestinal surgery
Immune‐enhancing supplements (oral or enteral) showed no clear difference in infectious complications recorded up to 30 days postdischarge compared with usual care or control (low certainty).
1 finding from 1 review
Length of hospital stay · people undergoing gastrointestinal surgery
1 finding from 1 review
Adverse effects · people undergoing gastrointestinal surgery
1 finding from 1 review
Non‐infectious complications · people undergoing gastrointestinal surgery
Immune‐enhancing supplements (oral or enteral) showed no clear difference in non‐ infectious complications recorded up to 30 days postdischarge compared with usual care or control (low certainty).
1 finding from 1 review